European Commission Approves Marketing Authorisation for Astra Zeneca’s Forxiga

Astra Zeneca has announced the European Commission has approved an update for Forxiga to include the positive outcomes and data from the Phase III Declare-Timi 58 trial.

In the trial, the drug achieved a significant reduction in the endpoint of hospitalisation for heart failure or Cardiovascular death in adults with type II diabetes. It also confirmed a well-balanced safety profile of the treatment.

‘Within the trial, Forxiga reduced the end point of hospitalisation for heart failure or cardiovascular death in patients suffering with type II diabetes” said Mene Pangalos, executive vice president, BioPharmaceuticals R&D “we look forward to benefitting patients with type II diabetes in the EU with this medicine.”